Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

Table 2 Clinical characteristics of the 51 recurrent or metastatic breast cancers

Characteristic at initial diagnosis	Number of patients	%
Total	51	100
Median age (years)	53.4 (32 to 79)
Median follow-up time (months)	51.7 (0.9 to 256)
Stage
I to III	34	67
IV	17	33
Estrogen receptor
Positive	32	63
Negative	17	33
Missing	2	4
Human epidermal growth factor receptor 2
Positive	15	29
Negative	33	65
Missing	3	6
PIK3CA mutation	16	31

ISSN: 1465-542X